At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
AMG820 and pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating AMG820 and pembrolizumab for Pancreatic Cancer and 2 related conditions. Completed, enrolled 117 participants across 15 sites in 6 countries.
Detailed Summary
A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, Germany, Spain, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionJan 2019
Study CompletionMay 2019
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartApr 14, 2016
Primary CompletionJan 2, 2019
Study CompletionMay 17, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.3 years ago
Interventions
AMG820 and pembrolizumabbiological
Treatment with AMG820 and pembrolizumab